Shelton D. Caruthers1, Dipanjan Pan1, Angana Senpan1, Anne H. Schmieder1, Patrick J. Gaffney2, Samuel A. Wickline1, Gregory M. Lanza1
1C-TRAIN, Washington University School of Medicine, St. Louis, MO, United States; 2Dept. of Surgery, St. Thomas' Hospital, London, United Kingdom
Based on a nanocolloidal suspension of lipid-encapsulated, organically-soluble copper oleate, a new site-targeted molecular imaging contrast agent is presented. Concentrating ~100,000 copper atoms per nanoparticle, this agent provides a high per-particle r1 relaxivity allowing sensitive detection on T1-weighted MRI as is demonstrated herein targeted to fibrin clots in vitro.